SSRIs in the course of COVID-19 pneumonia: Evidence of effectiveness of antidepressants on acute inflammation. A retrospective study

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Human Psychopharmacology: Clinical and Experimental Pub Date : 2023-12-07 DOI:10.1002/hup.2887

Leonardo Fei, Bernardo Bozza, Giulia Melani, Lorenzo Righi, Gabriele Santarelli, Ottone Baccaredda Boy, Davide Benedetti, Andrea Falone, Dario Flaccomio, Gabriele Giuranno, Michela Martelli, Pierpaolo Merola, Sandra Moretti, Endrit Ndoci, Vincenzo Pecoraro, Serena Siviglia, Andrea Berni, Alessandra Fanelli, Eleonora Giovagnini, Alessandro Morettini, Carlo Nozzoli, Ombretta Para, Carlo Rostagno, Camilla Tozzetti

{"title":"SSRIs in the course of COVID-19 pneumonia: Evidence of effectiveness of antidepressants on acute inflammation. A retrospective study","authors":"Leonardo Fei, Bernardo Bozza, Giulia Melani, Lorenzo Righi, Gabriele Santarelli, Ottone Baccaredda Boy, Davide Benedetti, Andrea Falone, Dario Flaccomio, Gabriele Giuranno, Michela Martelli, Pierpaolo Merola, Sandra Moretti, Endrit Ndoci, Vincenzo Pecoraro, Serena Siviglia, Andrea Berni, Alessandra Fanelli, Eleonora Giovagnini, Alessandro Morettini, Carlo Nozzoli, Ombretta Para, Carlo Rostagno, Camilla Tozzetti","doi":"10.1002/hup.2887","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Relationships between inflammation and mood have been observed in terms of pro-inflammatory effects induced by depressive conditions and, in parallel, by an antidepressant-induced favorable effect on the recovery of inflammatory states. Selective serotonin reuptake inhibitor (SSRI) drugs were hypothesized to improve the prognosis of COVID-19 pneumonia, a typical acute inflammation, in terms of decreased mortality rate and pro-inflammatory cytokine serum levels.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The medical records of COVID-19 pneumonia inpatients at Careggi University Hospital (Florence) were analyzed for prognosis and Interleukin 6 (IL-6) after admission for over a period of 22 months. Medical records of patients treated at admission and not discontinued until discharge with an SSRI or with vortioxetine were identified. Two groups, one treated with antidepressants, the other not treated, were evaluated according to the mentioned parameters. Multiple linear regression and logistic regression were performed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The entire sample composed of 1236 records (recovered patients 77.1%, deceased patients 22.9%). The treated group (<i>n</i> = 107) had a better prognosis than the untreated group in spite of age and comorbidity both being greater than in the untreated group. Correspondingly, IL-6 levels in the treated group were significantly lower (<i>p</i> < 0.01) than the levels in the untreated group, in every comparison.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Outcomes of this study support the hypothesis of the favorable influence of some antidepressants on the prognosis of COVID-19, possibly mediated by IL-6 modulation. Reduction in acute inflammation induced by the action of antidepressants was confirmed.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"39 1","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2887","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Relationships between inflammation and mood have been observed in terms of pro-inflammatory effects induced by depressive conditions and, in parallel, by an antidepressant-induced favorable effect on the recovery of inflammatory states. Selective serotonin reuptake inhibitor (SSRI) drugs were hypothesized to improve the prognosis of COVID-19 pneumonia, a typical acute inflammation, in terms of decreased mortality rate and pro-inflammatory cytokine serum levels.

Methods

The medical records of COVID-19 pneumonia inpatients at Careggi University Hospital (Florence) were analyzed for prognosis and Interleukin 6 (IL-6) after admission for over a period of 22 months. Medical records of patients treated at admission and not discontinued until discharge with an SSRI or with vortioxetine were identified. Two groups, one treated with antidepressants, the other not treated, were evaluated according to the mentioned parameters. Multiple linear regression and logistic regression were performed.

Results

The entire sample composed of 1236 records (recovered patients 77.1%, deceased patients 22.9%). The treated group (n = 107) had a better prognosis than the untreated group in spite of age and comorbidity both being greater than in the untreated group. Correspondingly, IL-6 levels in the treated group were significantly lower (p < 0.01) than the levels in the untreated group, in every comparison.

Conclusions

Outcomes of this study support the hypothesis of the favorable influence of some antidepressants on the prognosis of COVID-19, possibly mediated by IL-6 modulation. Reduction in acute inflammation induced by the action of antidepressants was confirmed.

查看原文本刊更多论文

SSRIs在COVID-19肺炎过程中的作用:抗抑郁药对急性炎症的有效性证据回顾性研究。

炎症和情绪之间的关系已经被观察到，在抑郁状态诱导的促炎作用方面，同时，抗抑郁药诱导的对炎症状态恢复的有利作用。假设选择性5 -羟色胺再摄取抑制剂(SSRI)药物可改善COVID-19肺炎(一种典型的急性炎症)的预后，降低死亡率和促炎细胞因子血清水平。方法:分析佛罗伦萨Careggi大学医院新冠肺炎住院患者22个月的预后及白细胞介素6 (IL-6)水平。确定了入院时未停用SSRI或沃替西汀的患者的医疗记录。两组，一组接受抗抑郁药物治疗，另一组未接受治疗，根据上述参数进行评估。进行多元线性回归和逻辑回归。结果:全样本共1236例，其中康复患者77.1%，死亡患者22.9%。治疗组(n = 107)的预后优于未治疗组，尽管年龄和合并症均大于未治疗组。相应的，治疗组IL-6水平显著降低(p)。结论:本研究结果支持了一些抗抑郁药物对COVID-19预后有利影响的假设，可能与IL-6调节有关。经证实，抗抑郁药引起的急性炎症减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Psychopharmacology: Clinical and Experimental 医学-精神病学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design